Bacitracin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Topical Local infections Apply 1-3 times/day. Ophth Ophth infections Apply thinly 1-3 times/day.
Dosage Details
Intramuscular
Staphylococcal infections
Child: Infant ≤2.5 kg: 900 U/kg daily in 2 or 3 divided doses; >2.5 kg: 1,000 U/kg daily in 2 or 3 divided doses.

Ophthalmic
Ophthalmic infections
Adult: Apply thinly to conjunctival sac 1-3 times daily.
Child: Same as adult dose.

Topical/Cutaneous
Local infections
Adult: Apply thinly to affected area 1-3 times daily.
Child: Same as adult dose.
Reconstitution
Reconstitute w/ NaCl 0.9% inj containing 2% procaine HCl. Concentration of soln should be between 5,000-10,000 U/mL.
Incompatibility
Slowly inactivated in bases containing stearyl alcohol, cholesterol, polyoxyethylene derivatives and Na laurilsulfate. Rapidly inactivated in bases containing water, macrogols, propylene glycol, glycerol, cetylpyridinium Cl, benzalkonium Cl, ichthammol, phenol and tannic acid.
Contraindications
Hypersensitivity to bacitracin.
Special Precautions
Patient w/ deep puncture wounds, bites or serious burns (topical). Prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. Renal impairment (IM). Pregnancy and lactation.
Adverse Reactions
Nephrotoxicity, albuminuria, cylinduria, azotemia, nausea, vomiting, skin rashes, pain at inj site (IM); hypersensitivity reactions.
IM/Ophth/Parenteral/PO/Topical: C
Patient Counseling Information
Maintain adequate fluid intake and urinary output.
MonitoringParameters
Perform urinalysis, renal function test and monitor urine output during IM use.
Drug Interactions
Increased risk of nephrotoxicity when used w/ other nephrotoxic drugs (e.g. colistin, kanamycin, neomycin, polymyxin B, and streptomycin). May enhance the action of neuromuscular blocking agents and anaesth.
Action
Description: Bacitracin inhibits bacterial cell wall synthesis by preventing transfer of mucopeptides into the growing cell wall. It also damages bacterial plasma membrane and active against protoplasts.
Pharmacokinetics:
Absorption: Rapidly absorbed (IM).
Distribution: Widely distributed into body tissues and readily diffuses into pleural and ascetic fluids.
Excretion: Via urine, approx 10-40%.
Chemical Structure

Chemical Structure Image
Bacitracin

Source: National Center for Biotechnology Information. PubChem Database. CID=11980094, https://pubchem.ncbi.nlm.nih.gov/compound/Bacitracin-methylene-disalicylate (accessed on Jan. 21, 2020)

Storage
Topical oint: Store between 15-30°C. Powder for inj: Store between 2-8°C. Ophth oint: Store between 20-25°C.
ATC Classification
J01XX10 - bacitracin ; Belongs to the class of other antibacterials. Used in the systemic treatment of infections.
D06AX05 - bacitracin ; Belongs to the class of other topical antibiotics used in the treatment of dermatological diseases.
References
Anon. Bacitracin (Ophthalmic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/08/2016.

Anon. Bacitracin (Systemic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/08/2016.

Anon. Bacitracin (Topical). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/08/2016.

Bacitracin inj (Xellia Pharmaceuticals ApS). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/08/2016.

Bacitracin ointment (Blossom Pharmaceuticals). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/08/2016.

Buckingham R (ed). Bacitracin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/08/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Bacitracin, Bacitracin Zinc (Topical). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 02/08/2016.

Disclaimer: This information is independently developed by MIMS based on Bacitracin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in